NCT03737370 - Fractionated Docetaxel and Radium 223 in Metastatic Castration-Resistant Prostate Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 30, 2018

Primary Completion Date

December 31, 2024

Study Completion Date

September 30, 2025

Conditions

Metastatic Castrate Resistant Prostate Cancer

Interventions

DRUG

Docetaxel

Docetaxel will be administered every 2 weeks (on Day 1 and Day 15 of a 28 day cycle). Fractionated dosing dependent on cohort.

RADIATION

Radium 223

Radium 223 will be delivered every 28 days (on day 1) for 6 cycles.

Trial Locations (4)

Ohio State University Comprehensive Cancer Center, Columbus

Henry Ford Health System, Detroit

Lahey Hospital & Medical Center, Boston

Tufts Medical Center, Boston